<a href="https://www.fiercebiotech.com/biotech/asco-telix-tees-pivotal-test-pluvicto-challenger-while-eyeing-white-space-radio-therapy" hreflang="en">ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas</a>
Telix Pharmaceuticals is advancing its pivotal phase 3 ProstACT trial for TLX591, a potential competitor to Novartis' Pluvicto, focusing on safety and efficacy in treating metastatic castration-resistant prostate cancer. The company is also exploring partnerships and expanding its pipeline with new radiopharmaceuticals, aiming to target a broader range of cancers beyond current therapies.
Telix Pharmaceuticals is advancing its radiopharmaceutical candidate TLX591 as a potential competitor to Novartis' Pluvicto for metastatic castration-resistant prostate cancer, with a focus on achieving FDA approval. This development is significant as TLX591 may offer a more favorable dosing and safety profile, potentially enhancing patient quality of life. Additionally, Telix's strategic partnership with Regeneron, valued at up to $2.1 billion, positions the company to expand its radiopharma pipeline into new cancer targets beyond prostate and neuroendocrine cancers.